165 related articles for article (PubMed ID: 29228662)
21. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.
Lin W; Chen M; Hong L; Zhao H; Chen Q
Front Oncol; 2018; 8():532. PubMed ID: 30519541
[TBL] [Abstract][Full Text] [Related]
22. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Kang SH; Keam B; Ahn YO; Park HR; Kim M; Kim TM; Kim DW; Heo DS
Oncoimmunology; 2019; 8(1):e1515057. PubMed ID: 30546955
[TBL] [Abstract][Full Text] [Related]
24. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.
Bancu A; Cowan R; Chaturvedi A
Arch Clin Cases; 2021; 8(1):14-18. PubMed ID: 34754934
[TBL] [Abstract][Full Text] [Related]
26. Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta.
Schulz D; Stancev I; Sorrentino A; Menevse AN; Beckhove P; Brockhoff G; Hautmann MG; Reichert TE; Bauer RJ; Ettl T
Oncotarget; 2019 Jan; 10(5):573-583. PubMed ID: 30728908
[TBL] [Abstract][Full Text] [Related]
27. HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses.
Lee JC; Wu ATH; Chen JH; Huang WY; Lawal B; Mokgautsi N; Huang HS; Ho CL
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33327484
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
[TBL] [Abstract][Full Text] [Related]
29. Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma.
Girolami I; Marletta S; Fiorentino V; Battocchio S; Cerbelli B; Fiamengo B; Gerosa C; Gianatti A; Morelli L; Riva G; Zagami MG; Fusco N; Munari E; L'Imperio V; Pagni F; Morbini P; Martini M; Eccher A
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836595
[TBL] [Abstract][Full Text] [Related]
30. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
Guo Q; Sun Y; Yu S; Bai H; Zhao J; Zhuo M; Wang J
Thorac Cancer; 2017 Mar; 8(2):73-79. PubMed ID: 28008744
[TBL] [Abstract][Full Text] [Related]
32. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
33. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
[TBL] [Abstract][Full Text] [Related]
34. Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy.
Tamari K; Minami K; Tatekawa S; Seo Y; Fukusumi T; Tanaka H; Suzuki M; Eguchi H; Takenaka Y; Hirata T; Hayashi K; Isohashi F; Shimizu S; Koizumi M; Inohara H; Ogawa K
Adv Radiat Oncol; 2024 Feb; 9(2):101353. PubMed ID: 38405303
[TBL] [Abstract][Full Text] [Related]
35. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Mandic R; Schamberger CJ; Müller JF; Geyer M; Zhu L; Carey TE; Grénman R; Dünne AA; Werner JA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6845-52. PubMed ID: 16203773
[TBL] [Abstract][Full Text] [Related]
36. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
38. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
39. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
40. ABCB11 accumulated in immature tertiary lymphoid structures participates in xenobiotic metabolic process and predicts resistance to PD-1/PD-L1 inhibitors in head and neck squamous cell carcinoma.
Ning J; Hao J; Guo F; Hou X; Li L; Wang J; Wang S; Gao Y; Zheng X; Gao M
Transl Oncol; 2023 Oct; 36():101747. PubMed ID: 37517143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
